The Asia Pacific Laboratory Developed Tests Market would witness market growth of 7.4% CAGR during the forecast period (2024-2031).
The China market dominated the Asia Pacific Laboratory Developed Tests Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of$1.66 billion by 2031. The Japan market is registering a CAGR of 7.1% during (2024 - 2031). Additionally, The India market would showcase a CAGR of 7.8% during (2024 - 2031).
The emergence of personalized and precision medicine approaches has fueled demand for LDTs that enable molecular profiling, genetic testing, and targeted therapy selection. Healthcare providers seek to individualize treatment strategies based on patient’s genetic makeup, biomarker profiles, and disease characteristics, driving the adoption of LDTs in oncology, pharmacogenomics, and other therapeutic areas.
The market is characterized by several notable trends, reflecting technological advancements, changes in healthcare delivery models, and evolving regulatory landscapes. These trends shape LDT development, adoption, and utilization, influencing market dynamics and strategic priorities for laboratories and healthcare stakeholders. For example, the LDTs market has witnessed rapid advancements in molecular diagnostics, fueled by innovations in genomics, proteomics, and other omics technologies. Laboratories are developing increasingly sophisticated assays and testing platforms capable of detecting and analyzing molecular markers, genetic variants, and biological pathways associated with health and disease.
As chronic diseases become more common in India, diagnostic testing becomes more important to aid in the early detection, assessment, and tracking of these conditions. Laboratory-developed tests are crucial in diagnosing chronic diseases, assessing disease severity, monitoring treatment response, and guiding clinical management decisions. According to Down to Earth, among Indians over 45, cardiovascular illnesses (CVD) are the most common. The prevalence of diagnosed CVD in the age group 45-49 is 19 percent and is 37 percent for the population above 75. Chronic hypertension follows a similar trajectory. Approximately 18% of people between 45 and 49 years old have hypertension, this number rises to 28% in those between 60 and 64 and 35% in those between 70 and 74 years old. As a result, the demand for LDTs tailored to the detection and characterization of chronic diseases is expected to increase.
Based on Application, the market is segmented into Oncology, Genetic Disorders/Inherited Disease, Infectious & Parasitic Diseases, Endocrine, Immunology, Nutritional & Metabolic Disease, Cardiology, Mental/Behavioral Disorder, Pediatrics-specific Testing, and Others. Based on Technology, the market is segmented into Molecular Diagnostics, Immunoassays, Hematology & Coagulation, Microbiology, Clinical Chemistry, Histology/Cytology, Flow Cytometry, Mass Spectroscopy, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The China market dominated the Asia Pacific Laboratory Developed Tests Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of$1.66 billion by 2031. The Japan market is registering a CAGR of 7.1% during (2024 - 2031). Additionally, The India market would showcase a CAGR of 7.8% during (2024 - 2031).
The emergence of personalized and precision medicine approaches has fueled demand for LDTs that enable molecular profiling, genetic testing, and targeted therapy selection. Healthcare providers seek to individualize treatment strategies based on patient’s genetic makeup, biomarker profiles, and disease characteristics, driving the adoption of LDTs in oncology, pharmacogenomics, and other therapeutic areas.
The market is characterized by several notable trends, reflecting technological advancements, changes in healthcare delivery models, and evolving regulatory landscapes. These trends shape LDT development, adoption, and utilization, influencing market dynamics and strategic priorities for laboratories and healthcare stakeholders. For example, the LDTs market has witnessed rapid advancements in molecular diagnostics, fueled by innovations in genomics, proteomics, and other omics technologies. Laboratories are developing increasingly sophisticated assays and testing platforms capable of detecting and analyzing molecular markers, genetic variants, and biological pathways associated with health and disease.
As chronic diseases become more common in India, diagnostic testing becomes more important to aid in the early detection, assessment, and tracking of these conditions. Laboratory-developed tests are crucial in diagnosing chronic diseases, assessing disease severity, monitoring treatment response, and guiding clinical management decisions. According to Down to Earth, among Indians over 45, cardiovascular illnesses (CVD) are the most common. The prevalence of diagnosed CVD in the age group 45-49 is 19 percent and is 37 percent for the population above 75. Chronic hypertension follows a similar trajectory. Approximately 18% of people between 45 and 49 years old have hypertension, this number rises to 28% in those between 60 and 64 and 35% in those between 70 and 74 years old. As a result, the demand for LDTs tailored to the detection and characterization of chronic diseases is expected to increase.
Based on Application, the market is segmented into Oncology, Genetic Disorders/Inherited Disease, Infectious & Parasitic Diseases, Endocrine, Immunology, Nutritional & Metabolic Disease, Cardiology, Mental/Behavioral Disorder, Pediatrics-specific Testing, and Others. Based on Technology, the market is segmented into Molecular Diagnostics, Immunoassays, Hematology & Coagulation, Microbiology, Clinical Chemistry, Histology/Cytology, Flow Cytometry, Mass Spectroscopy, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
List of Key Companies Profiled
- Neogenomics, Inc.
- Guardant Health, Inc.
- Qiagen N.V
- Quest Diagnostics Incorporated
- Abbott Laboratories
- Siemens Healthineers AG (Siemens AG)
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- F.Hoffmann-La Roche Ltd.
- Eurofins Scientific SE
Market Report Segmentation
By Application- Oncology
- Genetic Disorders/Inherited Disease
- Infectious & Parasitic Diseases
- Endocrine
- Immunology
- Nutritional & Metabolic Disease
- Cardiology
- Mental/Behavioral Disorder
- Pediatrics-specific Testing
- Others
- Molecular Diagnostics
- Immunoassays
- Hematology & Coagulation
- Microbiology
- Clinical Chemistry
- Histology/Cytology
- Flow Cytometry
- Mass Spectroscopy
- Others
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. Asia Pacific Laboratory Developed Tests Market by Application
Chapter 6. Asia Pacific Laboratory Developed Tests Market by Technology
Chapter 7. Asia Pacific Laboratory Developed Tests Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Neogenomics, Inc.
- Guardant Health, Inc.
- Qiagen N.V
- Quest Diagnostics Incorporated
- Abbott Laboratories
- Siemens Healthineers AG (Siemens AG)
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- F. Hoffmann-La Roche Ltd.
- Eurofins Scientific SE
Methodology
LOADING...
